Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb
Status:
Completed
Trial end date:
2017-02-08
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, monocentric translational study designed to evaluate
possible biomarkers of resistance to the first line of therapy with pazopanib in patients
with metastatic renal cell carcinoma (mRCC) who have not received systemic therapy in both
the adjuvant and metastatic phases.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano